Donald S Robinson

Summary

Publications

  1. ncbi Treatment effects of selegiline transdermal system on symptoms of major depressive disorder: a meta-analysis of short-term, placebo-controlled, efficacy trials
    Donald S Robinson
    Worldwide Drug Development, Burlington, VT, USA
    Psychopharmacol Bull 40:15-28. 2007
  2. ncbi Monoamine oxidase inhibitors: a new generation
    Donald S Robinson
    Psychopharmacol Bull 36:124-38. 2002
  3. ncbi A review of the efficacy and tolerability of immediate-release and extended-release formulations of gepirone
    Donald S Robinson
    Worldwide Drug Development, Melbourne, Florida 32940, USA
    Clin Ther 25:1618-33. 2003
  4. ncbi The selegiline transdermal system in major depressive disorder: a systematic review of safety and tolerability
    Donald S Robinson
    Worldwide Drug Development, 102 East Avenue, Burlington, VT 05401, United States
    J Affect Disord 105:15-23. 2008
  5. ncbi A 1-year, open-label study assessing the safety and tolerability of vilazodone in patients with major depressive disorder
    Donald S Robinson
    Worldwide Drug Development, Burlington, VT, USA
    J Clin Psychopharmacol 31:643-6. 2011
  6. ncbi Dosing strategies for antidepressant clinical trials: a commentary
    Donald S Robinson
    J Clin Psychopharmacol 24:1-3. 2004
  7. ncbi Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial
    Alan D Feiger
    Department of Psychiatry, University of Colorado School of Medicine, Denver, CO, USA
    J Clin Psychiatry 67:1354-61. 2006

Detail Information

Publications7

  1. ncbi Treatment effects of selegiline transdermal system on symptoms of major depressive disorder: a meta-analysis of short-term, placebo-controlled, efficacy trials
    Donald S Robinson
    Worldwide Drug Development, Burlington, VT, USA
    Psychopharmacol Bull 40:15-28. 2007
    ..This meta-analysis explores treatment effects of STS for individual symptoms of MDD derived from line-item analyses of the 28-item Hamilton Rating Scale for Depression (HAM-D28) and the Montgomery-Asberg Depression Rating Scale (MADRS)...
  2. ncbi Monoamine oxidase inhibitors: a new generation
    Donald S Robinson
    Psychopharmacol Bull 36:124-38. 2002
    ..The favorable safety profile of STS should allow this MAOI to be a broadly used antidepressant drug...
  3. ncbi A review of the efficacy and tolerability of immediate-release and extended-release formulations of gepirone
    Donald S Robinson
    Worldwide Drug Development, Melbourne, Florida 32940, USA
    Clin Ther 25:1618-33. 2003
    ..Gepirone, a 5-HT(1A) receptor agonist, has been assessed for use in the treatment of anxiety and depressive disorders. Azapirones, including gepirone, act to maintain neurotransmission at 5-HT(1A) receptors...
  4. ncbi The selegiline transdermal system in major depressive disorder: a systematic review of safety and tolerability
    Donald S Robinson
    Worldwide Drug Development, 102 East Avenue, Burlington, VT 05401, United States
    J Affect Disord 105:15-23. 2008
    ..Monoamine oxidase inhibitors (MAOIs) are highly efficacious antidepressants, but safety concerns have limited their broad use...
  5. ncbi A 1-year, open-label study assessing the safety and tolerability of vilazodone in patients with major depressive disorder
    Donald S Robinson
    Worldwide Drug Development, Burlington, VT, USA
    J Clin Psychopharmacol 31:643-6. 2011
    ..Montgomery-Åsberg Depression Rating Scale mean scores were 29.9 at baseline, 11.4 at week 8, and 7.1 at week 52 (observed cases). Vilazodone 40 mg/d for 1 year was safe and well tolerated by adults with major depressive disorder...
  6. ncbi Dosing strategies for antidepressant clinical trials: a commentary
    Donald S Robinson
    J Clin Psychopharmacol 24:1-3. 2004
  7. ncbi Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial
    Alan D Feiger
    Department of Psychiatry, University of Colorado School of Medicine, Denver, CO, USA
    J Clin Psychiatry 67:1354-61. 2006
    ..This study investigated the efficacy, safety, and tolerability of the selegiline transdermal system (STS) administered in a dose range of 6 mg/24 hours to 12 mg/24 hours for treating major depressive disorder (MDD)...